Search
Navigation
Join our mailing list!
(Your shopping cart is empty)
Home
>
Diane Publishing Books
>
New Drug Approval: FDA Needs to Enhance its Oversight of Drugs Approved on the Basis of Surrogate Endpoints
Our Price:
$
25.00
By
Marcia Crosse (au)
Year:
2009
Pages:
71
Binding
Paperback
Product Code:
1437924603
Description
Before approving a drug, the FDA assesses a drug's effectiveness. This assessment may be based on evidence showing that a drug has a positive impact on a surrogate endpoint (SE) -- a laboratory measure, such as blood pressure -- instead of more direct clinical evidence, like preventing strokes. After approval, FDA requires a drug sponsor to further study the drug. There have been concerns about FDA's reliance on SE and its oversight of post-marketing studies (PS). This report provides info. on: (1) all drug applications approved based on SE in FDA's accelerated approval process; (2) a subset of applications for potentially innovative drugs approved based on SE under FDA's traditional process; and (3) FDA's oversight of PS. Illustrations.
Related Products...
History of the New York Central System
Our Price:
$25.00
Add
Order of Christian Funerals: The Roman Ritual: Study Edition (rev. ed.)
Our Price:
$30.00
Add
War of the Rebellion: Official Records of the Union & Confederate Armies: Series I, Volume I
Our Price:
$30.00
Add
Gates of the Alamo
Our Price:
$14.00
Add
Karluk: The Great Untold Story of Arctic Exploration
Our Price:
$24.00
Add
Share your knowledge of this product with other customers...
Be the first to write a review
Diane Publishing Co
PO Box 617
Darby, PA 19023-0617
1-800-782-3833
About Us
Become an Affiliate
Privacy Policy
Send Us Feedback
Company Info
|
Advertising
|
Product Index
|
Category Index
|
Help
|
Terms of Use
Copyright � 2004 Diane Publishing Company. All Rights Reserved.
Built with
Volusion